Pathfinders in Biopharma

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Explore the Series

Inside Track: Behind the Scenes of a Major Biotech SPAC

RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with Nuvation Bio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig. These two industry leaders at the cutting edge of biotech innovation and venture capital share how they brought Nuvation Bio’s public market vision to fruition on the latest episode of RBC’s Pathfinders podcast.

What’s Material in ESG for Biopharma Firms?

In this episode of Pathfinders, Brian Abrahams, Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with the team of ESG leads at Gilead Sciences to understand the five key components driving the company’s ESG strategy, how this strategy has evolved and how it drives business impact.

Listen NowRead Article

Listen Time 18mRead Time 4m

Is Pharma at an ESG Turning Point?

In the global push to ESG-focused investing, the Pharma sector has traditionally been challenged. But RBC Capital Markets’ Daniel Busby, Pharmaceuticals Equity Research Analyst, suggests that this may be about to change. A combination of trends, some of them yet to appear on the public radar, could lift Pharma’s ESG market reputation and create new opportunities for investment and inclusion.

Read Article

Read Time 3m

Herd Immunity Update: Global Troubles, but Almost-Normal Arrives in U.S.

While the US is returning to quasi-normality, RBC Capital Markets analysts predict that ‘true’ herd immunity will take much longer. COVID will likely spike again in winter and tackling the pandemic on a global scale remains key to eradication.

Read Article

Read Time 3m

Biotech boom driving lab real estate boom

Our View: The accelerated pace of drug development and sizeable uptick in R&D funding are fueling substantial growth in the biotech industry. This growth, together with a preference by these companies to reside in top life science clusters that foster collaboration and innovation, is driving significant real estate demand and strong fundamentals in select US markets. RBC Capital Markets’ Equity Research team expects attractive development and growth opportunities for REITs in the life sciences industry in the next few years.

Read Article

Read Time 4m

RBC Imagine: Virtual Health is the Future

RBC Capital Markets’ Healthcare Equity Research Analyst Sean Dodge estimates that 35-40% of healthcare that has been delivered in-person could feasibly be virtualized. That’s an enormous slice of an annual $4T US spend – and an immense opportunity for innovation and investment to improve access to quality healthcare.

Read Article

Read Time 2m

Biotech’s Commitment to Sustainability and Innovation May Pave the Way for Achievement of ESG Goals

As sustainable fund flows surge to new highs, Brian Abrahams, Co-Head of Biotechnology Equity Research and Sara Mahaffy, U.S. Equity & ESG Strategist, examine biotech’s progress in adopting ESG principles and how it may impact performance in 2021.

Read Article

Read Time 3m

Biotech SPACs: A New Route to Going Public

As more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies access public markets long-term? Our investment banking team goes inside the SPAC boom to explain what companies need to know before choosing their path to going public.

Listen NowRead Article

Listen Time 30mRead Time 4m

Subscribe to Future Episodes of Pathfinders

Our podcast series explores the fast-moving world of Biopharma and what the road ahead looks like for companies and investors in the sector.

Subscribe Now

Recent Deals


A Leading Partner for the Biopharma Industry

Our specialty expertise, combined with outstanding execution, has resulted in recurring transactions for biopharma clients as we partner with them through each stage of their development and growth.


More from RBC Capital Markets

Navigating the Changing Face of Healthcare

Healthcare is in the midst of a revolution. From the challenges facing individual sectors to breakthrough innovations, gain the insights you need into the forces that are reshaping the industry.

A Leader in Global Insights

Access market and industry insights, commentary and analysis from our expert team to gain the perspective you need to make the most informed decisions.

Stay Informed

Get the latest insights from RBC Capital Markets delivered to your inbox.